BioCentury

7:00 AM GMT, May 7, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

EPS watch

EPS watch

Company 1Q07 EPS est 1Q07 EPS actual Outcome Growth from 1Q06 5/4 cls Wk chg % chg Mcap chg 5/4 Mcap
Biogen Idec (BIIB) $0.61 $0.59 Missed by $0.02 7% $46.91 -$1.08 -2% -$369.5 $16,050.8
Revenues rose 17% to $715.9M from $611.2M in 1Q06. The Street was expecting $730M. Sales of Avonex interferon beta-1a for multiple sclerosis (MS) were up 14% to $448.8M from $393.4M in 1Q06. U.S. sales of

Read the full 723 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.